INCY vs TVTX
Incyte vs Travere Therapeutics, Inc. — AI-powered side-by-side comparison
VS
TVTX
Travere Therapeutics, Inc.
62
Buy
| Metric | INCY | TVTX |
|---|
| AI Score |
72
|
62
|
| Price |
$121.08
|
$60.25
|
| P/E Ratio |
14.89×
|
-133.80×
|
| ROE |
24.9%
|
-22.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
94.4%
|
| Debt / Equity |
0.01×
|
25.16×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
59.0
|
| Beta |
0.769
|
1.042
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus TVTX.
INCY leads by 10 points.
INCY scores 72/100 (Buy) versus TVTX at 62/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
TVTX Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 17.2% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Bollinger bandwidth of 17.2% signals elevated volatility — Risk